Global Cetirizine Hydrochloride Market Insights Forecasts to 2033

• The Global Cetirizine Hydrochloride Market Size was Estimated at USD 6.14 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 2.53% from 2023 to 2033
• The Worldwide Cetirizine Hydrochloride Market Size is Expected to Reach USD 7.88 Billion by 2033
• Asia Pacific is predicted to grow at the fastest CAGR throughout the projection period

The Global Cetirizine Hydrochloride Market Size is Predicted to Exceed USD 7.88 Billion by 2033, Growing at a CAGR of 2.53% from 2023 to 2033. The market expansion is accelerated by the growing occurrence of allergic diseases in society, including allergic conjunctivitis, allergic rhinitis, and eczema, it is extensively used as an antihistaminic drug and is available as an over-the-counter drug and has a quicker therapeutic effect.

Market Overview

The global cetirizine hydrochloride market aims to develop, produce, and distribute cetirizine hydrochloride in a stable dosage form for the management of allergic diseases. Cetirizine hydrochloride is a selective second-generation antihistamine, acting as a histamine H (1)-receptor antagonist. Cetirizine is available in tablets, capsules, and liquid forms, with a daily dose of 10mg for adults with lower doses for kidney-related individuals. The marketed products of cetirizine hydrochloride are Okacet, Metrizin, NorthStar, Zyretc (chewable tablets), Cetzine (syrup), etc.

Several government strategies are executed for the safety concerns of the worldwide population, resulting in the growth of the cetirizine hydrochloride market. For instance, In August 2024, the Health Ministry banned 156 fixed-dose combinations (FDC) medicines, including anti-allergic (cetirizine HCL + paracetamol), antibiotics, analgesics, and multivitamins. Combining certain medications leads to unpredictable and potential adverse effects such as organ damage, cardiotoxicity, etc. The prohibition of manufacturing and distribution of FDC medicines led to the enhancement of the safety of patients worldwide. Considering this aspect benefits the population with disease conditions, resulting in eliminating the adverse reactions with the use of a single API medication and leading to market growth.

The rising incidence of allergic diseases escalates the need for antihistaminic drugs, especially cetirizine, as it exerts therapeutic action rapidly, leading to market expansion. For example, the data provided by the Global Allergy & Airways Patient Platform (GAAPP) reveals that the prevalence of allergy diseases is rising dramatically worldwide, affecting developed as well as developing nations and affecting 30–40% of the population.

Cetirizine hydrochloride's versatility and safety profile have increased its market potential, making it a reliable option for patients of any age group. Its commercial appeal has strengthened as a result of increasing competition brought about by the introduction of generic versions, which have reduced costs while rendering it more accessible to individuals from a wider range of economic circumstances.

The raised awareness regarding allergic conditions and adopting self-medication accelerated the cetirizine hydrochloride market growth.

Report Coverage

This research report categorizes the market for the global cetirizine hydrochloride market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global cetirizine hydrochloride market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global cetirizine hydrochloride market.

Driving Factors

Increasing prevalence of allergic diseases:

Globally, the prevalence of allergies is increasing, including eczema, food allergies, and allergic rhinitis (hay fever). Consequently, further individuals require treatment with drugs such as cetirizine hydrochloride in an attempt to alleviate their symptoms, including runny nose, sneezing, itching, etc. For instance, the U.S. Centers for Disease Control and Prevention (CDC) reported that more than 50 million people in the United States have allergies.

A rising proportion of the drug development process and a broad range of applications:

Researchers are focusing on enhancing the stability, efficacy, and safety of the drugs along with targeted drug delivery that drives the demand for cetirizine medications, resulting in market expansion. Cetirizine is an FDA-approved medication for allergic rhinitis and chronic urticaria, reducing hives and pruritus in idiopathic urticaria patients. It is considered a first-line agent by the American Academy of Allergy, Asthma & Immunology (AAAAI) and American College of Allergy Asthma and Immunology (ACAAI) guidelines and is approved for both ophthalmic and intravenous formulations. For instance, the data provided by the DARU Journal of Pharmaceutical Sciences affirmed that several researchers developed the transdermal patches of cetirizine hydrochloride using polymeric needles for a special population, including geriatric and pediatric populations as they are concerned with the difficulties in swallowing the tablets and dealing with nausea.

Restraining Factors

The side effects associated with cetirizine medications are mild drowsiness and stringent regulation requirements that might restrict the growth of the market.

Market Segmentation

The global cetirizine hydrochloride market share is classified into dosage form, applications, and end-user.

• The tablet segment dominated the global cetirizine hydrochloride market in 2023 and is predicted to grow at a substantial CAGR throughout the projected timeframe.

Based on the dosage form, the global cetirizine hydrochloride market is categorized into tablets, solutions, and capsules. Among these, the tablet segment dominated the global cetirizine hydrochloride market in 2023 and is predicted to grow at a substantial CAGR throughout the projected timeframe. The segmental expansion is attributed to ease of use, accuracy in dosing, availability in several dosages, accessibility to use in pediatrics and adults, over-the-availability availability, first-line drug, and most healthcare professionals prefer cetirizine hydrochloride tablets, greater stability, tablet coating minimizes the unpleasant taste, available in controlled release tablets, cost-effective, providing longer shelf life, ease of handling during transportation, and patient compliance.

• The allergic rhinitis segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the applications, the global cetirizine hydrochloride market is categorized as allergic conjunctivitis, allergic rhinitis, eczema, chronic urticaria, and others. Among these, the allergic rhinitis segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The rising occurrence of allergic rhinitis resulting the segments growth. For instance, allergic rhinitis is a major public health concern that affects around 400 million people, and adult incidence rates range from 10% to 40%. The segmental expansion is owing to raised aggregation of the pollen in the environment, exposure to allergens, air pollution, and alterations in global warming.

• The hospital pharmacies segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the projected timeframe.

Based on the end-user, the global cetirizine hydrochloride market is categorized as retail pharmacies, online pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment held the largest share in 2023 and is expected to grow at a significant CAGR during the projected timeframe. The segment growth is fueled by the increasing adoption by patients, accessibility of the nanoformulations of the cetirizine, compounding and dispensing the medicine facilities, medication monitoring services for the inpatient departments (IPD), statistical growth in the hospital admissions, and cost-effective medications as providing the discounts on medications.

Regional Segment Analysis of the Global Cetirizine Hydrochloride Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global cetirizine hydrochloride market over the predicted timeframe.

North America is anticipated to hold the largest share of the global cetirizine hydrochloride market over the predicted timeframe. Considering its high prevalence of allergic illnesses and sophisticated healthcare system, North America is anticipated to lead the growth of the cetirizine hydrochloride market. Customers in the USA are a major market player owing to their sophisticated pharmaceutical industry and increased awareness of allergy-related concerns. This domination is additionally facilitated by the high cost of healthcare and the demand for over-the-counter antihistamines. The need for efficient solutions is further reinforced by the rise in seasonal allergies brought on by pollution and climate change. The market potential is further enhanced by government initiatives to raise awareness of allergies and provide access to treatment.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. Rapid urbanization and growing healthcare costs in Asia-Pacific, including China and India, are driving up demand for cetirizine hydrochloride and its medications. Companies are establishing their products in a strategic position to take advantage of these developing markets by localizing their product offerings and extending their distribution networks.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global cetirizine hydrochloride market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Aurobindo Pharma Limited
• Cipla Limited
• Jubilant Pharma Sciences
• Lupin Pharmaceuticals
• Hetero Drugs
• Sun Pharmaceutical Industries
• Teva Pharmaceuticals
• Glenmark Pharmaceuticals
• Alembic Pharmaceuticals
• Sanofi
• Pfizer Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In October 2024, Indoco Remedies received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Tablets USP, 10mg (OTC). The product is a generic equivalent of the Reference Listed Drug, Zyrtec Allergy Tablets, 10 mg, manufactured by Johnson & Johnson Consumer Inc.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global cetirizine hydrochloride market based on the below-mentioned segments:

Global Cetirizine Hydrochloride Market, By Dosage Form

• Tablets
• Solutions
• Capsules

Global Cetirizine Hydrochloride Market, By Application

• Allergic Conjunctivitis
• Allergic Rhinitis
• Eczema
• Chronic Urticaria
• Others

Global Cetirizine Hydrochloride Market, By End-User

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

Global Cetirizine Hydrochloride Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa